SCLX (Scilex Holding Co) Tariff Resilience Score: 5/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
55 GF Score
Price $7.95
GF Value $5.89
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co Tariff Resilience Score?

Scilex Holding Co SCLX +2.15% 55 Tariff Resilience Score is 5 as of Jul. 22, 2026. GuruFocus rates SCLX with a GF Score™ of 55/100 and a GF Value™ of $5.89 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Scilex Holding Co ranks better than 84.41% on this metric.

Scilex Holding Co has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Scilex Holding Co has Scilex's pharmaceutical products rely on global supply chains, making it susceptible to tariffs on raw materials. However, its focus on the U.S. market and potential for alternative suppliers provide some resilience. Historical impacts have been moderate.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Scilex Holding Co might have Average Resilient.

Scilex Holding Co  (NAS:SCLX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Scilex Holding Co Tariff Resilience Score Related Terms

SCLX vs MIRA, NSRX, MDCX: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Scilex Holding Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's Tariff Resilience Score falls into.


SCLX
55GF Score
Scilex Holding Co SCLX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Scilex Holding Co (SCLX) has a Tariff Resilience Score of 5 as of Jul. 22, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Scilex Holding Co ranks #160 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Scilex Holding Co's Tariff Resilience Score too high?
Scilex Holding Co's current Tariff Resilience Score is 5. Based on the distribution chart, Scilex Holding Co ranks #160 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Scilex Holding Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Tariff Resilience Score compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #160 out of 1026 companies for Tariff Resilience Score. This places Scilex Holding Co in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Scilex Holding Co's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.89, compared to a current price of $7.95 — trading 35% above its estimated fair value. The current Tariff Resilience Score is 5. Scilex Holding Co's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Tariff Resilience Score is 5 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of $7.95 is trading 35% above its estimated GF Value™ of $5.89. GuruFocus considers Scilex Holding Co to be Significantly Overvalued.

Key valuation signals for SCLX:

  • Tariff Resilience Score: 5
  • GF Value™: $5.89 vs. price of $7.95 (35% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
55GF Score

Get the complete analysis for SCLX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.95
Price
$5.89
GF Value